



## COVID-19 Information



[Public health information \(CDC\)](#) | [Research information \(NIH\)](#)

[SARS-CoV-2 data \(NCBI\)](#) | [Prevention and treatment information \(HHS\)](#) | [Español](#)



**National Library of Medicine**  
National Center for Biotechnology Information

Log in

PubMed.gov

Search PubMed

Search

[Advanced](#)

Save

Email

Send to

Display options

[PLOS One](#). 2012;7(4):e35421. doi: 10.1371/journal.pone.0035421. Epub 2012 Apr 20.

# Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus

Chien-Te Tseng<sup>1</sup>, Elena Sbrana, Naoko Iwata-Yoshikawa, Patrick C Newman, Tania Garron, Robert L Atmar, Clarence J Peters, Robert B Couch

Affiliations [+ expand](#)

PMID: 22526222 | PMID: 23422500 | DOI: 10.1371/journal.pone.0035421

[Free PMC article](#)

[Full text links](#)

[Cite](#)

## Erratum in

PLoS One. 2012;7(8). doi:10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492

## Abstract

**Background:** Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease.

**Design:** Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated i.m. on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology.

**Results:** All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all


eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence.

**Conclusions:** These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.


## Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.


## Figures




**Figure 1. Vaccine Comparisons of Three SARS-CoV...**




**Figure 2. Vaccine Comparisons of Three SARS-CoV...**




**Figure 3. Higher Dosages of SV Vaccine...**



**Figure 4. Higher Dosages of SV Vaccine...**



**Figure 5. Photographs of Lung Tissue.** Representative...



**Figure 6. Photomicrographs of Lung Tissue.**

All figures (9)

## Similar articles

[Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.](#)

Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N.

J Virol. 2014 Aug;88(15):8597-614. doi: 10.1128/JVI.00983-14. Epub 2014 May 21.

PMID: 24850731 [Free PMC article.](#)

[Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.](#)

Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N.

J Virol. 2015 Mar;89(3):2025-2037. doi: 10.1128/JVI.02289-14. Epub 2014 Dec 17.

J Virol. 2015 Mar;89(6):2995-3007. doi: 10.1128/JVI.02980-14. Epub 2014 Dec 17.

PMID: 25520500 [Free PMC article.](#)

## Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.

Sekimukai H, Iwata-Yoshikawa N, Fukushi S, Tani H, Kataoka M, Suzuki T, Hasegawa H, Niikura K, Arai K, Nagata N.

Microbiol Immunol. 2020 Jan;64(1):33-51. doi: 10.1111/1348-0421.12754. Epub 2019 Nov 18.

PMID: 31692019 [Free PMC article.](#)

## Studies of SARS virus vaccines.

Zheng BJ, Du LY, Zhao GY, Lin YP, Sui HY, Chan C, Ma S, Guan Y, Yuen KY.

Hong Kong Med J. 2008 Aug;14 Suppl 4:39-43.

PMID: 18708674 [Review.](#)

## Vaccine design for severe acute respiratory syndrome coronavirus.

He Y, Jiang S.

Viral Immunol. 2005;18(2):327-32. doi: 10.1089/vim.2005.18.327.

PMID: 16035944 [Review.](#)

[See all similar articles](#)

**Cited by** 237 articles

## A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity.

Yang R, Deng Y, Huang B, Huang L, Lin A, Li Y, Wang W, Liu J, Lu S, Zhan Z, Wang Y, A R, Wang W, Niu P, Zhao L, Li S, Ma X, Zhang L, Zhang Y, Yao W, Liang X, Zhao J, Liu Z, Peng X, Li H, Tan W.

Signal Transduct Target Ther. 2021 May 31;6(1):213. doi: 10.1038/s41392-021-00634-z.

PMID: 34059617

## The COVID-19 vaccine development: A pandemic paradigm.

Carneiro DC, Sousa JD, Monteiro-Cunha JP.

Virus Res. 2021 May 17;301:198454. doi: 10.1016/j.virusres.2021.198454. Online ahead of print.

PMID: 34015363 [Free PMC article.](#) [Review.](#)

## Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.

Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K, Samnuan K, Blakney AK, Wright D, Sharpe HR, Gilbride C, Truby A, Allen ER, Gilbert SC, Shattock RJ, Lambe T.

Nat Commun. 2021 May 17;12(1):2893. doi: 10.1038/s41467-021-23173-1.

PMID: 34001897 [Free PMC article.](#)

## Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2.

McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ.

NPJ Vaccines. 2021 May 13;6(1):74. doi: 10.1038/s41541-021-00336-1.

PMID: 33986272 [Free PMC article.](#) Review.

## A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model.

Ragan IK, Hartson LM, Dutt TS, Obregon-Henao A, Maison RM, Gordy P, Fox A, Karger BR, Cross ST, Kapuscinski ML, Cooper SK, Podell BK, Stenglein MD, Bowen RA, Henao-Tamayo M, Goodrich RP.

Vaccines (Basel). 2021 Apr 1;9(4):340. doi: 10.3390/vaccines9040340.

PMID: 33916180 [Free PMC article.](#)

[See all "Cited by" articles](#)

## References

1. World Health Organization website. 2003. Available: [http://www.who.int/csr/media/sars\\_wha.pdf](http://www.who.int/csr/media/sars_wha.pdf). Accessed 2012 Apr 2. Severe acute respiratory syndrome (SARS): Status of the outbreak and lessons for the immediate future; unmasking a new disease. CSR/WHO, Geneva. 20 May 2003.
2. Tsang KW, Ho PL, Ooi CG, Yee WK, Wang T, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1953–66. - [PubMed](#)
3. Poutanen SM, Low D, Henry B, Finkelstein S, Rose D, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1953–66. - [PubMed](#)
4. World Health Organization Website. Available:

[http://www.who.int/csr/sars/country/2003\\_04\\_04/en/index.html](http://www.who.int/csr/sars/country/2003_04_04/en/index.html). Accessed 2004 April 21.

5. Lee N, Hui D, Wu A, Chan P, Cameron P, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. *N Engl J Med*. 2003;348:1986–94. - [PubMed](#)

Show all 49 references

## Publication types

- › [Research Support, N.I.H., Extramural](#)

## MeSH terms

- › [Animals](#)
- › [Chlorocebus aethiops](#)
- › [Eosinophils / immunology](#)
- › [Female](#)
- › [Lung / pathology\\*](#)
- › [Lung / virology](#)
  
- › [Mice, Inbred BALB C](#)
- › [Mice, Inbred C57BL](#)
- › [SARS Virus / immunology\\*](#)
- › [Severe Acute Respiratory Syndrome / prevention & control\\*](#)
- › [Severe Acute Respiratory Syndrome / virology](#)
- › [Th2 Cells / immunology](#)
- › [Tissue Culture Techniques](#)
- › [Vaccination / adverse effects\\*](#)
- › [Vaccines, Inactivated / adverse effects](#)
- › [Vaccines, Inactivated / immunology](#)
- › [Vero Cells](#)
- › [Viral Envelope Proteins / immunology](#)

- › [Viral Vaccines / adverse effects](#)
- › [Viral Vaccines / immunology\\*](#)

## **Substances**

- › [Vaccines, Inactivated](#)
- › [Viral Envelope Proteins](#)
- › [Viral Vaccines](#)

## **Related information**

[MedGen](#)

[PubChem Compound](#)

[PubChem Substance](#)

## **Grant support**

[N01AI30039/AI/NIAID NIH HHS/United States](#)

[N01 AI 30039/AI/NIAID NIH HHS/United States](#)

## **LinkOut – more resources**

### **Full Text Sources**

[Europe PubMed Central](#)

[PubMed Central](#)

[Public Library of Science](#)

### **Other Literature Sources**

[The Lens - Patent Citations](#)

[scite Smart Citations](#)

[NLM](#)



**Medical**

[MedlinePlus Health Information](#)

**Molecular Biology Databases**

[Mouse Genome Informatics \(MGI\)](#)

**Miscellaneous**

[NCI CPTAC Assay Portal](#)

[NCBI Literature Resources](#) [MeSH](#) [PMC](#) [BookShelf](#)

**FOLLOW NCBI**



Follow NLM



National Library of Medicine

8600 Rockville Pike

Bethesda, MD 20894

[Copyright](#)

[FOIA](#)

[Privacy](#)

[Help](#)

[Accessibility](#)

[Careers](#)

